References
- Davis K, Stewart D, Friedman J, et al. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003; 60: 443–456
- Selemon LD. Increased cortical neuronal density in schizophrenia. Am J Psychiatry 2004; 161: 1564
- Yucel M, Stuart GW, Maruff P, et al. Paracingulate morphologic differences in males with established schizophrenia: a magnetic resonance imaging morphometric study. Biol Psychiatry 2002; 52: 15–23
- Filley C, Kleinschmidt-DeMasters B. Neurobehavioral presentations of brain neoplasms. West J Med 1995; 163: 19–25
- Danckert J, Saoud M, Maruff P. Attention, motor control and motor imagery in schizophrenia: implications for the role of the parietal cortex. Schizophr Res 2004; 70: 241–261
- Fontanella M, Perozzo P, Ursoni R, Garbosa D, Bergui M. Neuropsychological assessment after microsurgical clipping of endovascular treatment of communicating anterior artery aneurysm. Acta Neurochirurg 2003; 145: 867–872
- Spreen O, Strauss E. A compendium of neuropsychological tests: administration, norms and commentary, 2nd edn. New York: Oxford University Press, 1998
- Bechara A, Tranel D, Damasio H. Characterization of the decision-making deficit of patients with ventromedial prefrontal cortex lesions. Brain 2000; 23: 2189–2202
- Kajs-Wyllie M. Ritalin revisited: does it really help in neurological injury?. J Neurosci Nurs 2002; 34: 303–311
- Zorowitz RD, Smout RJ, Gassaway JA, Horn SD. Neurostimulant medication usage during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP). Topics Stroke Rehabil 2005; 12: 28–36
- Gauthier L, Gauthier S. Assessment of functional changes in Alzheimer's disease. Neuroepidemiology 1990; 45: 1451–1455
- Patel V, Hope RA. A rating scale for aggressive behaviour in the elderly (the RAGE). Psychol Med 1992; 22: 211–221
- Inada T, Yagi G, Gardos G. Inter-rater reliability of the drug-induced extrapyramidal symptoms scale (DIEEPS). Coll Int Neuropsychopharmacol 1996; 1: 23–27
- De Deyn P, Jeste DV, Swanink R, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005; 25: 463–467